Crossmark

Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s40425-019-0812-9

Published Online: 2019-12-11

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Xuyao

Wang, Yichen

Fan, Jiajun

Chen, Wei

Luan, Jingyun

Mei, Xiaobin

Wang, Shaofei

Li, Yubin

Ye, Li

Li, Song

Tian, Wenzhi

Yin, Kai

Ju, Dianwen https://orcid.org/0000-0002-4305-9622
Funding

Funding for this research was provided by:

National Key Basic Research Program of China (2015CB931800)

National Natural Science Foundation of China (81773620, 81573332, 31872746)

Shanghai Science and Technology Funds (18431902800)

Scientific Research Projects of Shanghai Municipal Commission of Health and Family Planning (201740140)
License Information

Text and Data Mining valid from 2019-12-01
More Information

Article History

Received: 3 March 2019

Accepted: 11 November 2019

First Online: 11 December 2019

Ethics approval and consent to participate

: Procedures involving BALB/c nude mice and C57BL/6 mice (six-week old, male) were performed in accordance with the standards of Fudan University and approved by Animal Ethical Committee of School of Pharmacy Fudan University.

: Not applicable.

: Song Li is the employee, and Wenzhi Tian is the founder of ImmuneOnco Biopharma (Shanghai) Co., Ltd. The other authors declare no conflict of interests.